WuXi Biologics ESG Disclosure Earns Top Honors at HERA 2025

Takeaways

• WuXi Biologics has been recognized at the Hong Kong ESG Reporting Awards 2025 for Outstanding ESG Disclosure, highlighting its commitment to transparency.
• The award reinforces the company’s consistent progress in ESG reporting and sustainability leadership.
• Strong ESG disclosure is helping WuXi Biologics build trust with global clients, investors, and regulators.

WuXi Biologics (2269.HK) has received the Outstanding ESG Disclosure award at the Hong Kong ESG Reporting Awards (HERA) 2025, marking another milestone in the company’s sustainability journey. The recognition highlights WuXi Biologics’ continued focus on transparent and high-quality environmental, social, and governance (ESG) reporting.

This latest honor follows the company’s ESG Report Benchmark Award at HERA last year, underscoring the consistency of its ESG efforts. Together, these recognitions reflect how WuXi Biologics has steadily strengthened its disclosure practices while aligning sustainability with long-term business strategy.

In today’s global business environment, ESG disclosure is no longer just about regulatory compliance. Clear and credible reporting has become a competitive advantage, especially for companies operating across international markets. For WuXi Biologics, detailed ESG disclosure helps demonstrate accountability and builds confidence among stakeholders, including clients, investors, regulators, and partners.

Read More: What does an ESG disclosure score mean? Tracking ESG Performance

The company’s ESG reports outline progress across key areas such as corporate governance, talent development, and greenhouse gas (GHG) emission reduction. By clearly sharing both goals and performance, WuXi Biologics reassures stakeholders that sustainability commitments are backed by measurable action. This approach also supports its vision of shaping the future of Green CRDMO (Contract Research, Development, and Manufacturing Organization) services.

Commenting on the recognition, Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, emphasized the role of openness in sustainable growth. He noted that transparency is essential for building trust and that sharing ESG progress openly enables collaboration across the industry. According to Dr. Chen, the ESG Disclosure Award not only validates the company’s efforts so far but also motivates it to continue raising standards and leading the sector toward a more responsible future.

WuXi Biologics’ ESG leadership is further reflected in its participation in global sustainability initiatives, including the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative. These memberships underline the company’s proactive role in advancing responsible business practices across the pharmaceutical value chain.

The company has also received wide recognition from leading ESG rating and benchmarking organizations. WuXi Biologics holds an MSCI AAA ESG rating and has been awarded the EcoVadis Platinum Medal. It is listed in the Dow Jones Sustainability Indices and has been named to the CDP “A List” for Climate Change, Water Security, and Supplier Engagement.

Also Read: What Kind Of 'S' Disclosures Should Companies Expect?

Additional recognitions include top ratings from Sustainalytics, inclusion in the FTSE4Good Index Series, and listing in the Hang Seng ESG 50 Index. These achievements reinforce WuXi Biologics’ position as a global leader in ESG performance and disclosure.

Follow more news and views via our Reporting & Standards and Featured Articles, and stay updated on the top ESG events to attend in 2025 for industry insights and networking.

If you're looking for suitable ESG and Sustainability providers to share customized solutions specific to your business needs, check out KnowESG's Solutions page.

If you are an ESG provider looking to get your organization listed on our portal, visit this page.

Source: MarketScreener